GMT Capital Corp Boosts Holdings in Lantheus Holdings, Inc. (NASDAQ:LNTH)

GMT Capital Corp raised its holdings in Lantheus Holdings, Inc. (NASDAQ:LNTH - Free Report) by 11.7% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 457,500 shares of the medical equipment provider's stock after acquiring an additional 47,800 shares during the period. Lantheus makes up approximately 2.0% of GMT Capital Corp's investment portfolio, making the stock its 17th largest position. GMT Capital Corp owned about 0.66% of Lantheus worth $40,928,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also made changes to their positions in the company. State of New Jersey Common Pension Fund D increased its holdings in shares of Lantheus by 0.4% during the 4th quarter. State of New Jersey Common Pension Fund D now owns 26,428 shares of the medical equipment provider's stock worth $2,364,000 after buying an additional 115 shares during the last quarter. Bleakley Financial Group LLC grew its position in Lantheus by 6.1% in the fourth quarter. Bleakley Financial Group LLC now owns 2,237 shares of the medical equipment provider's stock worth $200,000 after acquiring an additional 129 shares during the period. Avantax Advisory Services Inc. raised its position in Lantheus by 5.9% in the fourth quarter. Avantax Advisory Services Inc. now owns 2,382 shares of the medical equipment provider's stock valued at $213,000 after purchasing an additional 132 shares during the period. Foundry Partners LLC lifted its stake in shares of Lantheus by 4.5% in the 4th quarter. Foundry Partners LLC now owns 3,103 shares of the medical equipment provider's stock valued at $278,000 after purchasing an additional 133 shares during the last quarter. Finally, UMB Bank n.a. grew its holdings in shares of Lantheus by 31.5% during the 4th quarter. UMB Bank n.a. now owns 559 shares of the medical equipment provider's stock worth $50,000 after purchasing an additional 134 shares during the period. 99.06% of the stock is currently owned by institutional investors and hedge funds.

Lantheus Trading Down 0.2 %

LNTH traded down $0.24 during trading hours on Monday, hitting $101.53. 295,963 shares of the company's stock were exchanged, compared to its average volume of 952,729. The firm has a market cap of $6.95 billion, a P/E ratio of 16.88 and a beta of 0.20. Lantheus Holdings, Inc. has a 12-month low of $65.76 and a 12-month high of $126.89. The firm has a 50 day moving average of $97.37 and a 200 day moving average of $95.14.

Lantheus (NASDAQ:LNTH - Get Free Report) last posted its quarterly earnings data on Thursday, February 27th. The medical equipment provider reported $1.34 earnings per share for the quarter, missing analysts' consensus estimates of $1.57 by ($0.23). Lantheus had a return on equity of 44.29% and a net margin of 28.57%. The company had revenue of $391.11 million for the quarter, compared to analysts' expectations of $376.61 million. As a group, research analysts expect that Lantheus Holdings, Inc. will post 6.01 EPS for the current fiscal year.

Insider Buying and Selling

In related news, Director Mary Anne Heino sold 53,107 shares of the business's stock in a transaction on Monday, March 3rd. The shares were sold at an average price of $94.35, for a total transaction of $5,010,645.45. Following the completion of the transaction, the director now owns 440,399 shares in the company, valued at approximately $41,551,645.65. The trade was a 10.76 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, CFO Robert J. Jr. Marshall sold 10,000 shares of the firm's stock in a transaction on Monday, March 17th. The shares were sold at an average price of $100.52, for a total value of $1,005,200.00. Following the completion of the sale, the chief financial officer now owns 113,860 shares in the company, valued at approximately $11,445,207.20. This represents a 8.07 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 63,109 shares of company stock worth $6,016,046. Company insiders own 1.50% of the company's stock.

Analyst Upgrades and Downgrades

Several brokerages recently issued reports on LNTH. Truist Financial boosted their price objective on shares of Lantheus from $120.00 to $127.00 and gave the company a "buy" rating in a report on Thursday, February 27th. B. Riley reduced their price target on shares of Lantheus from $127.00 to $122.00 and set a "buy" rating on the stock in a research note on Friday, March 21st. Finally, JMP Securities reaffirmed a "market outperform" rating and set a $112.00 price objective on shares of Lantheus in a research report on Tuesday, January 14th. One analyst has rated the stock with a hold rating and seven have given a buy rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and a consensus target price of $129.43.

Lantheus Profile

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.